A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study of Oral MOA-728 for the Treatment of Opioid- Induced Bowel Dysfunction in Subjects With Chronic Nonmalignant Pain
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
The effect of the interventional treatment will be measured by bowel movements.
1 month
No
Medical Monitor
Study Director
Wyeth is now a wholly owned subsidiary of Pfizer
United States: Food and Drug Administration
3200A3-2201
NCT00547586
October 2007
February 2008
Name | Location |
---|---|
Hinsdale, Illinois 60521 | |
Birmingham, Alabama 35294 | |
Phoenix, Arizona 85012 | |
Fountain Valley, California 92708 | |
Miami, Florida 33176 | |
Cleveland, Ohio 44195 | |
Nashville, Tennessee 37203-1632 | |
Austin, Texas 78705 | |
Flint, Michigan 48532 | |
McLean, Virginia 22101 | |
Albuquerque, New Mexico 87131-5636 | |
Metairie, Louisiana 70006 | |
Baltimore, Maryland 21287 | |
Boston, Massachusetts | |
Charlotte, North Carolina | |
Eugene, Oregon | |
Indianapolis, Indiana | |
Las Vegas, Nevada 89109 | |
Jackson, Mississippi |